These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 29895330

  • 1. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
    Shigiyama F, Kumashiro N, Fuchigami A, Hirose T.
    Cardiovasc Diabetol; 2018 Jun 12; 17(1):86. PubMed ID: 29895330
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A, Shigiyama F, Kitazawa T, Okada Y, Ichijo T, Higa M, Hiyoshi T, Inoue I, Iso K, Yoshii H, Hirose T, Kumashiro N.
    Cardiovasc Diabetol; 2020 Jan 07; 19(1):1. PubMed ID: 31910850
    [Abstract] [Full Text] [Related]

  • 3. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S, Shigiyama F, Hisatake S, Mizumura S, Shiraga N, Hori M, Ikeda T, Hirose T, Kumashiro N.
    Cardiovasc Diabetol; 2021 Feb 02; 20(1):32. PubMed ID: 33530982
    [Abstract] [Full Text] [Related]

  • 4. Rationale and design of the randomised controlled cross-over trial: Cardiovascular effects of empaglifozin in diabetes mellitus.
    Thirunavukarasu S, Brown LA, Chowdhary A, Jex N, Swoboda P, Greenwood JP, Plein S, Levelt E.
    Diab Vasc Dis Res; 2021 Feb 02; 18(3):14791641211021585. PubMed ID: 34182806
    [Abstract] [Full Text] [Related]

  • 5. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I.
    Endocr Pract; 2017 Jul 02; 23(7):831-840. PubMed ID: 28332871
    [Abstract] [Full Text] [Related]

  • 6. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
    Bonora BM, Vigili de Kreutzenberg S, Avogaro A, Fadini GP.
    Cardiovasc Diabetol; 2019 Aug 14; 18(1):106. PubMed ID: 31412874
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
    Sahay RK, Giri R, Shembalkar JV, Gupta SK, Mohan B, Kurmi P, Kumar SR, Sawardekar VM, Mishra A, Murthy LS, Arya VV, Sonawane AR, Soni PN, Gofne SK, Karnawat SR, Rajurkar MN, Patel PM, Lakhwani LK, Mehta SC, Joglekar SJ.
    Adv Ther; 2023 Jul 14; 40(7):3227-3246. PubMed ID: 37258803
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
    Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, Hirose T.
    Cardiovasc Diabetol; 2017 Jul 06; 16(1):84. PubMed ID: 28683796
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
    Tanaka A, Shimabukuro M, Teragawa H, Okada Y, Takamura T, Taguchi I, Toyoda S, Tomiyama H, Ueda S, Higashi Y, Node K, EMBLEM Investigators.
    Cardiovasc Diabetol; 2021 Jul 31; 20(1):160. PubMed ID: 34332584
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
    Ueda S, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Morimoto T.
    Cardiovasc Drugs Ther; 2018 Feb 31; 32(1):73-80. PubMed ID: 29435776
    [Abstract] [Full Text] [Related]

  • 18. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.
    Bailey CJ, Del Prato S, Wei C, Reyner D, Saraiva G.
    Diabetes Obes Metab; 2019 Nov 31; 21(11):2564-2569. PubMed ID: 31364269
    [Abstract] [Full Text] [Related]

  • 19. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M, Tahara N, Tahara A, Igata S, Honda A, Sugiyama Y, Nakamura T, Sun J, Kumashiro Y, Matsui T, Fukumoto Y, Yamagishi SI.
    Curr Vasc Pharmacol; 2019 Nov 31; 17(4):411-420. PubMed ID: 29766812
    [Abstract] [Full Text] [Related]

  • 20. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
    Levine MJ.
    Curr Diabetes Rev; 2017 Nov 31; 13(4):405-423. PubMed ID: 27296042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.